Further analysis showed that FN3K knockdown resensitized human NSCLC lines (H3255 and PC9) to erlotinib treatment (29), highlighting the therapeutic potential of targeting FN3K in cancer cells that exhibit survival dependency on NRF2. This evidence concerns the gene FN3K and cancer.